Detect cancer early.
When it matters most.
The CA62 test utilizes advanced chemiluminescence technology to detect epithelial carcinomas at Stages I & II with unprecedented sensitivity. Peace of mind, delivered to your door.
100% Negative Predictive Value*
Biomarker Analysis
0.12 ng/mL
Result generated
July 14, 2024
Epithelial Carcinoma Detection
Sensitivity: High